HOME
ANZ BCTG PROFILE
NEWS AND MEDIA RELEASES
CLINICAL TRIALS
Prevention
Early Breast Cancer
Advanced
ANNUAL PARTICIPANTS' SCIENTIFIC MEETING
CONSUMER ADVISORY PANEL
BREAST CANCER INSTITUTE OF AUSTRALIA
POSITIONS VACANT
USEFUL LINKS
BECOME A MEMBER
CONTACT INFORMATION
SEARCH
LOGIN
Username :
Password :
Forgot Your Password?
Printer Friendly
Prevention
ANZ 02P2 : IBIS-II
An international multi-centre trial of anastrozole vs placebo in postmenopausal women at increased risk of breast cancer and tamoxifen vs anastrozole in postmenopausal women with hormone sensitive DCIS.
ANZ 0501 : LATER - Later adjuvant Aromatase inhibitor Therapy for postmenopausal women with Endocrine Responsive breast cancer
Randomised trial of letrozole plus usual care versus usual care without letrozole to prevent new breast cancer events in postmenopausal women who have completed a minimum of 4 years of adjuvant endocrine therapy for early, hormone responsive breast cancer more than 1 year previous, and who are disease-free at trial entry.
ANZ BCTG receives research infrastructure funding from the Cancer Institute NSW
and the Australian Government through Cancer Australia
Copyright ©
2010
Australian New Zealand Breast Cancer Trials Group Limited. All Rights Reserved.
Copyright & Disclaimer
|
Privacy Policy